Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07601100 |
| Title | A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant (Isa Iber VD) |
| Acronym | Isa Iber VD |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Beth Israel Deaconess Medical Center (BIDMC) | Boston | Massachusetts | 02215 | United States | Details | |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details |